Moderna
Search results
We at BioNTech believe that the immune system is the fundamental driver for therapeutic success in cancer, and infectious diseases and other serious diseases.
BioNTech was able to generate total gross proceeds of 150 million dollars from the IPO. [30] In 2021, BioNTech announced it would open its Asia headquarters in Singapore, and also open a vaccine manufacturing plant there, with support from the Singapore Economic Development Board. [31]
Nov 14, 2022 · SINGAPORE – BioNTech on Monday confirmed that its first mRNA manufacturing plant in Singapore will be operational in late 2023, with the facility also serving as the German company’s regional ...
With decades of deep immunology expertise and experience in developing and optimizing mRNA as part of its broad suite of novel technologies, the company is working with the global community to defeat life-threatening and serious diseases such as cancer, COVID-19, malaria and tuberculosis.
BioNTech was founded on the idea of using mRNA to activate the immune system against a patient’s individual tumor – an approach that we believe can also be tailored to target several kinds of diseases.
May 10, 2021 · SINGAPORE - BioNTech, the vaccine maker that has partnered with Pfizer on its Covid-19 shot, will be designating Singapore as its regional headquarters for South-east Asia, and will set up an...
May 10, 2021 · BIONTECH will pump in "hundreds of millions of dollars" to set up its South-east Asia headquarters and open a vaccine manufacturing facility in Singapore, as part of plans to establish a footprint in Asia.
Aug 18, 2022 · This article provides a summary of the interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19 issued by WHO Strategic Advisory Group of Experts on Immunization (SAGE).
Nov 13, 2020 · A vaccine candidate developed by the company they co-founded 12 years ago, BioNTech, was more than 90 per cent effective in preventing the disease — a far higher level than the widely-used jabs...
Nov 18, 2020 · The only Grade 3 (severe) solicited adverse events greater than or equal to 2% in frequency after the first or second dose was fatigue at 3.8% and headache at 2.0% following dose 2. Consistent with earlier shared results, older adults tended to report fewer and milder solicited adverse events following vaccination.
